What is PTC Therapeutics's change in receivables?

PTC Therapeutics (PTCT) reported change in receivables of $40.39M in Q1 2026.

How has PTC Therapeutics's change in receivables changed year-over-year?

PTC Therapeutics's change in receivables decreased by 15.5% year-over-year, from $47.79M to $40.39M.

What does change in receivables mean?

Change in total receivables including trade and non-trade receivables.

PTC Therapeutics PTCT Change in receivables

Change in receivables at other companies

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInReceivables.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's change in receivables?: PTC Therapeutics (PTCT) reported change in receivables of $40.39M in Q1 2026.
How has PTC Therapeutics's change in receivables changed year-over-year?: PTC Therapeutics's change in receivables decreased by 15.5% year-over-year, from $47.79M to $40.39M.
What does change in receivables mean?: Change in total receivables including trade and non-trade receivables.